Standard Article

Protein–ligand docking and structure-based drug design

Part 3. Proteomics

3.7. Structural Proteomics

Specialist Review

  1. Peter R. Oledzki,
  2. Alasdair T. R. Laurie,
  3. Richard M. Jackson

Published Online: 15 JUL 2006

DOI: 10.1002/047001153X.g307218

Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics

Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics

How to Cite

Oledzki, P. R., Laurie, A. T. R. and Jackson, R. M. 2006. Protein–ligand docking and structure-based drug design. Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics. 3:3.7.

Author Information

  1. University of Leeds, Leeds, UK

Publication History

  1. Published Online: 15 JUL 2006

Abstract

Protein-ligand docking and de novo drug design have become increasingly important tools in aiding the drug design process, particularly with the recent increase in the number of pharmaceutically relevant macromolecular structures that have become available. Here, we review current methods and their applications, and highlight some recent successes in structure-based drug design.

Keywords:

  • virtual screening;
  • de novo drug design;
  • scoring functions;
  • docking search procedures